文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

比克替拉韦/恩曲他滨/丙酚替诺福韦在HIV-1初治者中的三年耐药性研究

Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

两项3期随机双盲对照研究显示,B/F/TAF在初治HIV-1感染者中144周内非劣于DTG/ABC/3TC或DTG+F/TAF,且无治疗 emergent 耐药。基线耐药突变(INSTI-R 1.3%,NRTI-R 2.7%,NNRTI-R 14.1%,PI-R 3.5%)不影响疗效,一例基线INSTI耐药者仍维持病毒抑制。

要点

  • B/F/TAF在初治HIV-1感染者中144周疗效非劣于DTG方案且无治疗期耐药。
  • 基线传播性耐药突变率:INSTI-R 1.3%,NRTI-R 2.7%,NNRTI-R 14.1%,PI-R 3.5%。
  • 基线耐药突变不影响治疗反应,一例基线INSTI耐药者仍维持HIV-1 RNA<50 copies/mL至144周。

核心结论

  • B/F/TAF、DTG/ABC/3TC或DTG+F/TAF在初治HIV-1感染者中均达到高且持久的病毒学抑制,基线耐药突变不影响疗效且无治疗期耐药。

研究设计与样本

  • 两项3期随机双盲活性对照研究(1489和1490)的3年耐药分析,对筛查时HIV-1蛋白酶和逆转录酶进行群体测序,并对蛋白酶、逆转录酶和整合酶进行回顾性基线下一代测序(≥15%阈值)。
  • 耐药分析对象为截至第144周或末次访视确认HIV-1 RNA≥200 copies/mL病毒反弹或未再抑制至<50 copies/mL的参与者。

主要发现

  • 传播性原发耐药突变比例:INSTI-R 1.3%(17/1270),NRTI-R 2.7%(35/1274),NNRTI-R 14.1%(179/1274),PI-R 3.5%(44/1274)。
  • 这些与研究药物无关的预存耐药突变不影响治疗结局。
  • B/F/TAF组一例参与者基线存在比克替拉韦和多替拉韦耐药突变(整合酶Q148H+G140S),至第144周维持HIV-1 RNA<50 copies/mL。
  • 共21例参与者符合耐药检测条件[1.3%(8/634)B/F/TAF;1.9%(6/315)DTG/ABC/3TC;2.2%(7/325)DTG+F/TAF],均无治疗期耐药。

临床怎么用

  • 初治HIV-1感染者使用B/F/TAF时,基线耐药突变不影响疗效,支持其作为一线选择。
  • 治疗前可进行耐药检测,但基线INSTI耐药突变的存在不排除B/F/TAF的有效性。

局限性

  • 耐药分析基于回顾性下一代测序(≥15%阈值)和群体测序,可能低估低频突变。
  • 符合耐药检测条件的参与者数量较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Two Phase 3, randomized, double-blind, active-controlled studies of initial HIV-1 treatment demonstrated that bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) was non-inferior to dolutegravir/abacavir/lamivudine (DTG/ABC/3TC; Study 1489) or to DTG+F/TAF (Study 1490) through 144 weeks. In both studies, there was no emergent resistance to study drugs. Here, the 3 year resistance analysis and impact of baseline resistance substitutions on treatment response are described. METHODS: Population sequencing of HIV-1 protease and reverse transcriptase (RT) was performed at screening. Retrospective baseline next generation sequencing of protease, RT and integrase (IN) was analysed at a ≥ 15% cutoff. Resistance analyses were performed on participants with confirmed viral rebound of HIV-1 RNA ≥200 copies/mL through Week 144 or last visit who did not resuppress to <50 copies/mL while on study drug. RESULTS: Transmitted primary drug resistance substitutions were present in the following proportions of participants: integrase strand transfer inhibitor (INSTI) resistance (-R) in 1.3% (17/1270) of participants; NRTI-R in 2.7% (35/1274); NNRTI-R in 14.1% (179/1274); and PI-R in 3.5% (44/1274). These pre-existing resistance substitutions not associated with study drug did not affect treatment outcomes. One participant in the B/F/TAF group had pre-existing bictegravir and dolutegravir resistance substitutions (Q148H+G140S in integrase) at baseline and suppressed and maintained HIV-1 RNA <50 copies/mL through Week 144. In total, 21 participants qualified for resistance testing [1.3% (8/634) B/F/TAF; 1.9% (6/315) DTG/ABC/3TC; 2.2% (7/325) DTG+F/TAF]; none had emergent resistance to study drugs. CONCLUSIONS: Treatment with B/F/TAF, DTG/ABC/3TC, or DTG+F/TAF achieved high, durable rates of virological suppression in HIV-1 treatment-naive participants. The presence of pre-existing resistance substitutions did not affect treatment outcomes, and there was no treatment-emergent resistance.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Acosta RK, Chen GQ, Chang S, et al. Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants. J Antimicrob Chemother. 2021. PMID: 33880558. doi:10.1093/jac/dkab115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。